Narayana Hrudayalaya Limited
Financial trend (76/100) does the heavy lifting; valuation (24/100) is the drag.
ExpensiveNarayana Hrudayalaya Limited earns a Hold from StocksWizard, with a blended score of 48/100. We put fair value near ₹1,531.42; at ₹1,869.2 that leaves roughly 18% downside, so the stock screens overvalued by 18%. On 49.1x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 10% below its 52-week high of ₹2,080.3 and 17% above the low of ₹1,601.75. Financial health scores 77/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹2,149.43 implies about 15% upside across 14 analysts. It clears 8 of 13 investability checks, with durability 52, valuation 28 and momentum 51 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,225.14.
Analyst views
1-year price
EOD · 2026-09-1452-week range
-10.15% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold48Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 19.8%
- Fail: Low debt (D/E < 0.5): 1.29x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 76%
- Pass: Earnings growing: 14%
- Pass: Net margin ≥ 10%: 10.2%
- Pass: Current ratio > 1.5: 2.15
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 4.07
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter67.2%
- Institutions13.6%
- Public & other19.2%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (19.8%).
- Financially solid — Altman Z 4.07.
Opportunities
- Revenue growing (76% YoY).
Bear case
Weaknesses
- High debt relative to equity.
Threats
- Rich valuation versus sector peers.
About Narayana Hrudayalaya Limited
Narayana Hrudayalaya Limited operates medical and healthcare facilities in India and the Cayman Islands through its Medical and Healthcare Related Services segment. The company provides specialized services including oncology, cardiology, cardiac surgery, anesthesiology, audiology, blood banking, clinical genetics, clinical immunology, clinical nutrition and dietetics, clinical psychology, and cosmetology.
Narayana Hrudayalaya Limited — frequently asked questions
Is Narayana Hrudayalaya Limited a buy, hold or sell?
StocksWizard currently rates Narayana Hrudayalaya Limited (NH) a Hold, based on a blended score of 48/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Narayana Hrudayalaya Limited's fair value?
Our blended DCF and relative-valuation model estimates Narayana Hrudayalaya Limited's fair value at about ₹1,531.42, versus a current price of ₹1,869.2 — roughly 18% downside. On that basis the stock looks overvalued by 18%.
Is Narayana Hrudayalaya Limited financially healthy?
Narayana Hrudayalaya Limited scores 77/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Narayana Hrudayalaya Limited's share price performed?
Narayana Hrudayalaya Limited is roughly flat over three months, and last traded at ₹1,869.2. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.